

## 英語論文 総説

1. **Saji S, Kimura-Tsuchiya R, Sasaki E.** Molecular diagnostics for precision medicine in breast cancer treatment: what does the future hold? (Editorial). *Breast Cancer*. 23(1):1-3, 2016.
2. Sato F, **Saji S**, Toi M. Genomic tumor evolution of breast cancer. *Breast Cancer*. 23(1):4-11, 2016.
3. Ozaki A, Tanimoto T, **Saji S**. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer (Correspondence). *N Engl J Med*, 373:1672-1673, 2015.
4. Toi M, Masuda N, Ishiguro H, **Saji S**, Ohno S, Chow LW. Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. *Int J Biol Markers*. 30(2): e252-3, 2015.
5. **Saji S, Kimura-Tsuchiya R.** Combination of molecular-targeted drugs with endocrine therapy for hormone-resistant breast cancer. *Int J Clin Oncol*. 20(2):268-72, 2015.
6. Niikura N, **Saji S**, Tokuda Y, Iwata H. Brain Metastases in Breast Cancer. *Jpn J Clin Oncol*. 44(12): 1133-1140, 2014.

## 英語論文 原著

1. Ueno T, **Saji S**, Sugimoto M, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Imoto S, Sasano H, Toi M. Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. *BMC Cancer*. 16(1):230, 2016.
2. Uehiro N, Sato F, Pu F, Tanaka S, Kawashima M, Kawaguchi K, Sugimoto M, **Saji S**, Toi M. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer. *Breast Cancer Research*. 18(1):129, 2016.
3. Dohi O, Yagi N, Onozawa Y, **Kimura-Tsuchiya R**, Majima A, Kitaichi T, Horii Y, Suzuki K, Tomie A, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Linked color imaging improves endoscopic diagnosis of active *Helicobacter pylori* infection. *Endoscopy International Open*. 4(7): E800-E805, 2016.
4. Fujita Y, Kishimoto M, Nakao R, **Kimura-Tsuchiya R**, Yagi N, Yanagisawa A. Incidence of lymphatic involvement in differentiated-type intramucosal gastric cancers as examined by endoscopic resection. *Gastric Cancer*. 19(1):192-197, 2016.
5. Tomie A, Dohi O, Yagi N, Kitae H, Majima A, Horii Y, Kitaichi T, Onozawa Y, Suzuki K, **Kimura-Tsuchiya R**, Okayama T, Yoshida N, Kamada K, Katada K, Uchiyama K, Ishikawa T, Takagi T, Handa O, Konishi H, Naito Y, Itoh Y. Blue Laser Imaging-Bright Improves Endoscopic Recognition of Superficial Esophageal Squamous Cell Carcinoma. *Gastroenterology Research and Practice*. 2016:6140854, 2016.
6. Takahashi N, Kameoka J, Takahashi N, Tamai Y, Murai K, Honma R, **Noji H**, Yokoyama H, Tomiya Y, Kato Y, Ishizawa K, Ito S, Ishida Y, Sawada K, Harigae H. Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. *International Journal of Hematology*. 10(3):344-357, 2016.
7. Ikeda K, Harada-Shirado K, Matsumoto H, **Noji H**, Ogawa K, Takeishi Y. Molecular response of e19a2 BCR-ABL1 chronic myeloid leukemia with double Philadelphia chromosome by dasatinib. *Journal of Clinical Oncology*. 34(14): e130-e133, 2016.
8. Tajima K, Takahashi N, Ishizawa K, Murai K, Akagi T, **Noji H**, Sasaki O, Wano M, Itoh J, Kato Y, Shichishima T, Ishida Y, Harigae H, Sawada K; The Tohoku Hematology Forum. High

prevalence of diffuse large B-cell lymphoma in occult hepatitis B virus-infected patients in the Tohoku district in Eastern Japan. *Journal of Medical Virology*. 88(12):2206-2210, 2016.

9. Ohkawara H, Shichishima-Nakamura A, Ikeda K, Sukegawa M, Furukawa M, Sano T, Ueda K, Kimura S, Yoshihisa A, **Noji H**, Ogawa K, Takeishi Y. Infected pancreatic pseudocyst ruptured into stomach and colon associated with splenic artery pseudoaneurysm. *Journal of the Pancreas*. 17(3):324-327, 2016.
10. Abe Y, Miura T, Yoshida MA, Ujii R, Kurosu Y, Kato N, Katafuchi A, Tsuyama N, Kawamura F, Ohba T, Inamasu T, Shishido F, **Noji H**, Ogawa K, Yokouchi H, Kanazawa K, Ishida T, Muto S, Ohsugi J, Suzuki H, Ishikawa T, Kamiya K, Sakai A. Analysis of chromosome translocation frequency after a single CT scan in adults. *Journal of Radiation Research*. 57(3):220-226, 2016.
11. Ozaki A, Leppold C, Tsubokura M, Tanimoto T, **Saji S**, Kato S, Kami M, Tsukada M, Ohira H. Social isolation and cancer management after the 2011 triple disaster in Fukushima, Japan: A case report of breast cancer with patient and provider delay. *Medicine (Baltimore)*. 95(26): e4027, 2016.
12. Shikama Y, Cao M, Ono T, Feng X, **Noji H**, Kimura H, Ogawa K, Suzuki Y, Ikeda K, Takeishi Y, Kimura J. Reduction of c-Fos via overexpression of miR-34a results in enhancement of TNF- $\alpha$  production by LPS in neutrophils from myelodysplastic syndrome patients. *PLOS ONE*. 11(18): e0158527, 2016.
13. Yagata H, Ohtsu H, Komoike Y, **Saji S**, Takei H, Nakamura T, Ohashi Y, Iwase T, Shimozuma K. Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. *Supportive Care in Cancer*. 24(2):683-689, 2016.
14. Matsuyama T, Ishikawa T, Okayama T, Oka K, Adachi S, Mizushima K, **Kimura R**, Okajima M, Sakai H, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Kokura S, Naito Y, Itoh Y. Tumor inoculation site affects the development of cancer cachexia and muscle wasting. *Int J Cancer*. 137(11):2558-65, 2015.
15. Honma N, Horii R, Ito Y, **Saji S**, Younes M, Iwase T, Akiyama F. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy. *BMC Cancer*. 15(1):698, 2015.
16. Hojo T, Masuda N, Mizutani T, Shibata T, Kinoshita T, Tamura K, Hara F, Fujisawa T, Inoue K, **Saji S**, Nakamura K, Fukuda H, Iwata H. Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204. *Jpn J Clin Oncol*. 45(10):983-6 2015.
17. Hayashi N, Niikura N, Masuda N, Takashima S, Nakamura R, Watanabe K, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitani R, Yasojima H, Yamauchi H, **Saji S**, Iwata H. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 49(1):277-84. 2015.
18. Kurebayashi J, Miyoshi Y, Ishikawa T, **Saji S**, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S. Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. *Breast Cancer*. 22(3):235-44. 2015.
19. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; **CLEOPATRA Study Group**. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med*. 372(8):724-34, 2015.
20. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F. Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy. *Breast Cancer*, 22(1):71-8, 2015.

21. Takemoto K, Hatano E, Iwaisako K, Takeiri M, Noma N, Ohmae S, Toriguchi K, Tanabe K, Tanaka H, Seo S, Taura K, Machida K, Takeda N, **Saji S**, Uemoto S, Asagiri M. Necrostatin-1 protects against reactive oxygen species (ROS)-induced hepatotoxicity in acetaminophen-induced acute liver failure. *FEBS Open Bio*. Sep 6; 4: 777-87. 2014.
22. Niikura N, Hayashi N, Masuda N, Takashima S, Nakamura R, Watanabe KI, Kanbayashi C, Ishida M, Hozumi Y, Tsuneizumi M, Kondo N, Naito Y, Honda Y, Matsui A, Fujisawa T, Oshitanai R, Yasojima H, Tokuda Y, **Saji S**, Iwata H. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. *Breast Cancer Res Treat*. 147(1):103-12, 2014.
23. Honma N, Horii R, Iwase T, **Saji S**, Younes M, Ito Y, Akiyama F. Proportion of estrogen or progesterone receptor expressing cells in breast cancers and response to endocrine therapy. *Breast*. 23(6):754-62, 2014.
24. Ueno T, Masuda N, Yamanaka T, **Saji S**, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Sasano H, Toi M. Evaluating the 21-gene assay Recurrence Score as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer, *Int J Clin Oncol*. 9(4):607-13, 2014.
25. **Kimura-Tsuchiya R**, Ishikawa T, Kokura S, Mizushima K, Adachi S, Okajima M, Matsuyama T, Okayama T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Yagi N, Naito Y, Itoh Y. The inhibitory effect of heat treatment against epithelial-mesenchymal transition (EMT) in human pancreatic adenocarcinoma cell lines. *J Clin Biochem Nutr*. 55(1):56-61, 2014.

#### 日本語論文 総説

1. 鹿目将至、**佐治重衡**  
ホルモン抵抗性乳がんに対する内分泌療法と分子標的薬との併用  
*腫瘍内科*、18(3):214-219, 2016.
2. 阿部宣子、大竹徹、**佐治重衡**  
特集：乳癌発症リスクとその対策 女性ホルモンと乳癌  
*乳癌の臨床*、31(3): 187-192, 2016.
3. **佐治重衡**  
One point lesson スライドの作り方  
*Cancer Board of the Braest*, 2(1), 69-71, 2016.
4. 鈴木礼子、**佐治重衡**  
やせ・肥満と乳がん発生リスク—女性のライフステージ別に異なる可能性について—  
*癌と化学療法*、42(5):525-528, 2015.
5. 大津敦、赤司浩一、**佐治重衡**、吉村清  
座談会 抗体治療の新展開  
*がん分子標的治療*、13(2):224-231, 2015.
6. **佐治重衡**  
総説論文というもの (エッセイ)  
*日本癌病態治療研究会誌*、21(1):47-48, 2015.
7. 山口絢音、**佐治重衡**、戸井雅和  
閉経前ホルモン受容体陽性早期乳がんに対する術後内分泌療法  
*腫瘍内科*、15(5):438-443, 2015.

8. 津田萌、石黒洋、**佐治重衡**  
内分泌療法薬の作用機序と副作用：概論  
日本臨床 73(suppl 2), 291-297, 2015.
9. 今村知世、**佐治重衡**  
ホルモン受容体陽性乳がんに対するタモキシフェン治療と CYP2D6 遺伝子多型  
がん分子標的治療, 12(4): 449-455, 2014.
10. 佐藤史顕、**佐治重衡**、戸井雅和  
State of the Art: Genetic tumor evolution  
Cancer Board 乳癌, 7(2), 23-30, 2014.
11. 林直輝、山内英子、**佐治重衡**  
乳癌患者におけるアロマターゼ阻害薬と骨粗鬆症  
The BONE, 28(4), 69-74, 2014.
12. **佐治重衡**、**木村礼子**  
閉経前、腋窩リンパ節転移陽性、Luminal A 乳癌の治療 b) 術前薬物療法  
外科, 76(13): 1550-1553, 2014.
13. 清水華子、諏訪裕文、**佐治重衡**  
抗 HER2 療法の新時代 ALTTO 試験の結果から  
腫瘍内科, 14(3):268-272, 2014.
14. 河口浩介、鈴木栄治、**佐治重衡**  
乳がんの抗 HER2 療法耐性機序とその克服  
がん分子標的治療 Vol. 12No. 2: 13-19, 2014
15. 土肥 統、八木信明、**木村礼子**、鎌田和浩、内藤裕二、伊藤義人  
残胃の早期胃癌に対する ESD の実際  
消化器の臨床, 17(3):264-268, 2014.

## 書籍

1. **佐治重衡** (監修)  
ホルモン療法薬 (p420-421)、乳房のがん (p476-487)  
薬がみえる vol.3 第1版、メデイックメディア, 2016.
2. **木村礼子**、**佐治重衡**  
第II章乳癌薬物療法の実際 分子標的治療—4 臨床試験と実際の投与方法 ベバシズ  
マブ  
オンコロジークリニカルガイド 乳癌薬物療法 (第2版), 木下貴之, 戸井雅和  
編, pp296-303, 南山堂, 2016.
3. **野地秀義**、七島 勉  
第5章 血液科疾患の診療 A 赤血球系疾患 4. 発作性夜間ヘモグロビン尿症.  
血液科研修ノート, 神田善伸 責任編集, p. 238-242, 診断と治療社, 2016.
4. **佐々木栄作**、**佐治重衡**  
G-2-1 ホルモン受容体陽性乳癌に対する治療戦略  
乳癌診療のための分子病理エッセンシャル, 津田均、木下貴之、田村研治編、南山堂、  
p195-205、2016.

5. **佐治重衡**  
2-2 B. 原発乳癌 術後内分泌療法  
乳腺腫瘍学 第2版、日本乳癌学会編、金原出版株式会社、228-236、2016.
6. **佐々木栄作**  
CQ23 DS療法(DTX+S-1)をどう使いこなすか？  
CQ24 weekly PTX療法をどう使いこなすか？  
胃がん薬物療法 Q&A、佐藤温編、ヴァンメディカル、72-75、2015.
7. **佐々木栄作**  
第1章抗がん剤の副作用と治療 8. 神経障害 116-121  
第4章レジメン別の副作用 2. 頭頸部がん 346-348  
改訂版 がん化学療法副作用対策ハンドブック、岡元るみ子・佐々木常雄編、羊土社、2015.
8. 山口絢音、**佐治重衡**  
IV. A. 2 術後ホルモン療法は何年間で適切か？  
EBM がん化学療法・分子標的治療法 2016-2017edition、西條長宏監修、  
朴成和、大江裕一郎、南博信、直江和樹編、中外医学社、338-343、2015.
9. 澤木正孝、**佐治重衡**  
22. 乳癌  
新臨床腫瘍学-がん薬物療法専門医のために-(改訂第4版)、日本臨床腫瘍学会編、  
南江堂、362-373、2015.
10. **佐治重衡**  
乳癌の分子生物学と mTOR  
エベロリムスによる乳癌治療の新展開、野口眞三郎編、メディカルレビュー社、30-37、  
2014.